Apixaban vs Enoxaparin for Bladder Cancer
(CARE Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this randomized trial is to compare bladder cancer patient experiences taking prophylactic anticoagulation at home after surgery to remove their bladder. The main questions it aims to answer are:* Are patients equally adherent to apixaban as they are enoxaparin? Why or why not?* Do patients prefer apixaban or enoxaparin?* What is the typical patient cost to take apixaban vs enoxaparin after surgery?Participants will be randomized to receive a prescription for either enoxaparin or apixaban which they will then fill themselves and self-administer at home until post-operative day 30. They will receive phone calls from study coordinators at days 30 and 90 to complete questionaries over the phone to assess trial outcomes.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it excludes those already on a therapeutic dose of anticoagulants. If you're taking antiplatelet agents, you may still be eligible to participate.
Is Apixaban safe for use in humans?
How does the drug Apixaban differ from Enoxaparin for bladder cancer treatment?
Apixaban is an oral medication, which makes it easier for patients to take compared to Enoxaparin, which is an injectable drug. This oral administration can improve patient adherence and satisfaction, especially after bladder cancer surgery, by potentially extending the duration of blood clot prevention without the need for injections.12356
What data supports the effectiveness of the drug Apixaban for preventing blood clots after bladder cancer surgery?
Research shows that Apixaban, an oral medication, is effective and safe for preventing blood clots after bladder cancer surgery, with no major bleeding events or symptomatic blood clots reported in patients. This suggests it could be a good alternative to injectable medications like Enoxaparin, potentially improving patient adherence and satisfaction.12347
Who Is on the Research Team?
Katharine F Michel, MD
Principal Investigator
University of Pennsylvania
Are You a Good Fit for This Trial?
This trial is for bladder cancer patients who've had surgery to remove their bladder. They must be able to self-administer anticoagulation medication at home and participate in phone surveys. Specific inclusion and exclusion criteria details are not provided.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a prescription for either enoxaparin or apixaban and self-administer at home until post-operative day 30
Follow-up
Participants are monitored for safety and effectiveness after treatment, with phone calls at days 30 and 90 to assess trial outcomes
What Are the Treatments Tested in This Trial?
Interventions
- Apixaban
- Enoxaparin
Apixaban is already approved in European Union, United States for the following indications:
- Deep vein thrombosis
- Pulmonary embolism
- Nonvalvular atrial fibrillation
- Deep vein thrombosis
- Pulmonary embolism
- Nonvalvular atrial fibrillation
- Stroke prevention
Find a Clinic Near You
Who Is Running the Clinical Trial?
Abramson Cancer Center at Penn Medicine
Lead Sponsor
American Urological Association
Collaborator